Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
September 24th 2024During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
Read More
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
CheckMate 77T Trial of Perioperative Nivolumab Generates EFS Benefit in Resectable NSCLC
September 15th 2024In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.
Read More